Journal of Chemical Health Risks

www.jchr.org

JCHR (2026) 16(2), 4834-4850 | ISSN:2251-6727

Recent Advances in Molecular Docking: Methods, Applications, And Challenges in the Research and Discovery of Phytochemical Compounds

Rashmi Dorai[1*], Anu Rai[1], Rohit Kumar[1], Rachna Ahirwar[1], Ritwik Kashyap[1], Rishi Kumar[1]

Nims Institute of Pharmacy, Nims University, Rajasthan, Jaipur

Corresponding author: Rashmi Dorai*, Asst. Professor, NIMS Institute of Pharmacy, NIMS University, Rajasthan, Jaipur

(Received: 16 February 2026 Revised: 14 March 2026 Accepted: 25 April 2026)

KEYWORDS

Molecular Docking, Phytochemicals, Drug Discovery, Computational Chemistry, Protein-Ligand Interactions, Natural Products, Binding Affinity Prediction

ABSTRACT:

Molecular docking has emerged as a cornerstone computational technique in modern drug discovery, particularly for identifying therapeutic potential in phytochemical compounds derived from plants. This research examines recent methodological advances in molecular docking, their applications in phytochemical research, and persistent challenges limiting widespread adoption. We explore how improvements in scoring functions, flexible docking algorithms, and machine learning integration have enhanced prediction accuracy for protein-ligand interactions. The study demonstrates that contemporary docking approaches successfully identify promising phytochemical candidates with significantly improved hit rates compared to traditional screening methods. However, challenges remain regarding water molecule treatment, protein flexibility representation, and accurate binding affinity prediction. Through comprehensive analysis of recent phytochemical docking studies targeting various therapeutic areas including cancer, diabetes, and infectious diseases, we illustrate both the tremendous potential and current limitations of computational screening approaches. Our findings suggest that hybrid methodologies combining molecular docking with molecular dynamics simulations and experimental validation provide the most reliable pathway for phytochemical drug discovery. This research contributes to understanding how computational approaches can accelerate the identification of plant-derived therapeutic compounds while highlighting areas requiring further methodological development to improve prediction reliability and reduce experimental validation costs.

1. INTRODUCTION

The search for new therapeutic compounds has increasingly turned toward nature's pharmacy, where plants have produced complex chemical molecules for millions of years. Traditional medicine systems across cultures have long recognized that certain plants possess healing properties, yet understanding exactly how plant compounds interact with human biological targets remained largely mysterious until recent decades. Molecular docking emerged as a powerful computational tool that allows researchers to predict how phytochemical compounds might bind to specific proteins involved in disease processes.

Phytochemicals represent an incredibly diverse chemical library that evolution has refined through natural selection. These compounds serve various functions in plants including defense against pathogens, attraction of pollinators, and protection from environmental stress. Many possess structural complexity and stereochemical diversity that synthetic chemistry struggles to replicate efficiently (Newman and Cragg, 2020).

Approximately 60% of currently approved drugs derive either directly from natural products or were inspired by natural product structures, highlighting the pharmaceutical relevance of plant-derived compounds.

Traditional drug discovery involves screening thousands of compounds experimentally to identify those showing biological activity against disease targets. This process consumes enormous time, resources, and materials. A typical drug development program costs over $2 billion and requires 10-15 years from initial discovery to market approval. These economics make drug development increasingly unsustainable, particularly for diseases affecting smaller patient populations or developing countries with limited purchasing power (Wouters OJ et al., 2022).

Molecular docking offers a computational alternative that can screen millions of compounds virtually before

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 4834-4850 | ISSN:2251-6727

committing resources to physical synthesis and testing. The technique predicts how small molecules orient themselves when binding to protein targets, estimating binding affinity and identifying favorable interaction patterns. Successful docking can narrow thousands of candidate compounds to dozens of promising leads worth experimental validation, dramatically accelerating discovery timelines and reducing costs (Meng et al., 2021).

However, molecular docking is not without limitations. Early docking programs produced concerning false positive rates, where compounds predicted to bind strongly showed little experimental activity. Scoring functions that estimate binding strength often failed to accurately rank compounds. Protein flexibility, which significantly impacts binding in reality, was frequently ignored due to computational expense. Water molecules mediating protein-ligand interactions received inadequate treatment. These limitations created skepticism about docking reliability for serious drug discovery applications (Rajput VP et al.,2025).

Recent years have witnessed substantial methodological advances addressing many historical limitations. Improved scoring functions incorporate machine learning trained on extensive experimental binding data. Flexible docking algorithms account for protein conformational changes upon ligand binding. Enhanced computational power enables more thorough conformational sampling. Integration with molecular dynamics simulations provides dynamic perspectives on binding stability. These advances have significantly improved docking accuracy, making it an increasingly reliable tool for phytochemical screening (Fujimoto et al., 2022).

The application of modern docking techniques to phytochemical research has accelerated dramatically. Researchers have virtually screened plant compound libraries against targets relevant to cancer, diabetes, cardiovascular disease, neurodegenerative conditions, and infectious diseases. Many studies have successfully identified phytochemicals with experimental activity predicted by docking, validating the computational approach. However, translation from docking prediction to actual therapeutic agents remains challenging, requiring extensive optimization and validation (Chihomvu P et al., 2024)

This research examines the current state of molecular docking in phytochemical drug discovery. We review recent methodological advances, analyze applications across therapeutic areas, evaluate prediction accuracy against experimental outcomes, and identify persistent challenges limiting reliability. The goal is providing researchers with realistic understanding of what modern docking can and cannot accomplish, guiding effective integration of computational approaches into phytochemical research programs (Liu H et al., 2024).

2. OBJECTIVES

This research pursues several interconnected objectives:

- **Primary Objective:** Comprehensively evaluate recent methodological advances in molecular docking techniques and assess their impact on phytochemical drug discovery success rates compared to traditional experimental screening approaches.
- **Secondary Objective 1:** Analyze the application of contemporary docking methods across diverse therapeutic areas including cancer, metabolic disorders, and infectious diseases, identifying which disease targets benefit most from computational screening.
- **Secondary Objective 2:** Critically assess the accuracy of binding affinity predictions from current docking algorithms by comparing computational results against experimental validation data from recent phytochemical studies.
- **Secondary Objective 3:** Identify persistent challenges and limitations in molecular docking methodologies that continue to hinder prediction reliability and propose potential solutions based on emerging computational techniques.
- **Secondary Objective 4:** Develop practical guidelines for researchers integrating molecular docking into phytochemical discovery workflows, including appropriate validation strategies and realistic expectation setting.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 4834-4850 | ISSN:2251-6727

3. SCOPE OF STUDY

The research scope encompasses:

- **Methodological Scope:** Focus on protein-ligand docking techniques applicable to small molecule drug discovery, including rigid docking, flexible docking, and induced-fit docking approaches, excluding protein-protein docking and nucleic acid docking which involve different computational challenges.
- **Compound Scope:** Emphasis on phytochemicals derived from plant sources including flavonoids, alkaloids, terpenoids, phenolic compounds, and glycosides, rather than synthetic compound libraries or other natural product classes like marine-derived compounds.
- **Application Scope:** Analysis covers therapeutic applications where phytochemical docking has been extensively applied, particularly cancer, diabetes, cardiovascular disease, neurodegenerative disorders, and infectious diseases.
- **Temporal Scope:** Review focuses on methodological advances and applications from 2020-2025, capturing recent developments while acknowledging foundational earlier work that established the field.
- **Exclusions:** The study does not address quantum mechanical calculations for binding energy estimation, covalent docking methods, or fragment-based drug design approaches, which represent specialized techniques beyond mainstream phytochemical screening applications.

4. LITERATURE REVIEW

4.1 Evolution of Molecular Docking Methodologies

Molecular docking emerged in the 1980s when computational power first enabled prediction of protein-ligand complexes. Early approaches treated both proteins and ligands as rigid bodies, searching for geometric complementarity between molecular surfaces. These rigid docking methods captured basic binding geometries but missed crucial details about conformational flexibility that real molecules exhibit (Meng XY et al.,2011).

The recognition that ligands adopt different conformations when binding to proteins led to flexible ligand docking in the 1990s. Algorithms explored multiple ligand conformations during docking, identifying orientations that fit optimally within binding pockets. This flexibility substantially improved prediction accuracy, though computational costs increased dramatically. Various search algorithms emerged including genetic algorithms, Monte Carlo sampling, and systematic conformational searches, each balancing thoroughness against computational efficiency.

Protein flexibility represented a more challenging problem. Proteins undergo conformational changes upon ligand binding through induced-fit mechanisms where binding pockets reshape to accommodate ligands. Accurately modeling this flexibility requires enormous computational resources since proteins contain thousands of atoms that could potentially move. Most practical docking programs continued treating proteins as rigid structures, accepting reduced accuracy as a necessary compromise (Sotriffer CA, 2011).

Recent advances have partially addressed protein flexibility through several approaches. Ensemble docking uses multiple protein conformations from crystal structures or molecular dynamics simulations, docking ligands against each conformation separately. This captures some protein flexibility without the computational expense of fully flexible protein docking. Induced-fit docking protocols perform initial rigid docking followed by local protein optimization around the bound ligand, allowing binding pocket residues to adjust their positions. These hybrid approaches substantially improve accuracy for targets exhibiting significant conformational changes (Fujimoto KJ et al., 2022).

4.2 Scoring Functions and Binding Affinity Prediction

Scoring functions estimate binding affinity between proteins and ligands, providing the critical evaluation that determines whether predicted binding poses represent favorable interactions. Three main scoring

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 4834-4850 | ISSN:2251-6727

function classes have evolved, each with distinct advantages and limitations (Zhang and Li, 2024).

Force field-based scoring functions calculate interaction energies using molecular mechanics, summing contributions from van der Waals forces, electrostatic interactions, hydrogen bonding, and desolvation effects. These physics-based approaches provide interpretable energy components but often fail to accurately predict binding affinities due to approximations in molecular mechanics and incomplete treatment of entropic effects.

Empirical scoring functions fit parameters to experimental binding data, typically including terms for hydrogen bonds, hydrophobic contacts, ionic interactions, and binding entropy. By training on known protein-ligand complexes, empirical functions often achieve better correlation with experimental binding affinities than force field approaches. However, they may not generalize well beyond the chemical space of their training data (Pason LP et al., 2016).

Knowledge-based scoring functions derive interaction preferences from statistical analysis of protein-ligand crystal structures. These functions assume that frequently observed interactions represent favorable binding contributions. Knowledge-based approaches work well for compounds similar to known drugs but struggle with novel chemical scaffolds lacking precedent in structural databases.

Machine learning has recently revolutionized scoring function development. Deep learning models trained on massive binding affinity datasets capture complex interaction patterns that traditional scoring functions miss. These learned functions often outperform classical approaches, though they require extensive training data and computational resources (Chen et al., 2023).

4.3 Phytochemicals in Drug Discovery

Phytochemicals have yielded numerous therapeutic agents throughout pharmaceutical history. Aspirin derives from willow bark compounds, morphine comes from opium poppies, and paclitaxel originated from Pacific yew trees. These successes demonstrate that plants produce medicinally relevant compounds, yet traditional isolation and characterization methods proved extremely laborious (Atanasov et al., 2021).

Modern phytochemical research benefits from comprehensive compound databases cataloguing thousands of plant-derived molecules with their structures, properties, and reported biological activities. Databases like PubChem, ChEMBL, and specialized natural product collections provide researchers with ready access to phytochemical diversity. These digital libraries enable virtual screening approaches that would be impossible with physical compound samples (Sorokina M et al., 2020).

Phytochemicals pose unique challenges for computational screening. Many contain multiple chiral centers, glycosidic modifications, and conformational flexibility exceeding typical synthetic drugs. Their larger size and greater flexibility create more complex conformational spaces that docking algorithms must search. Additionally, phytochemicals often contain unusual functional groups not well-represented in scoring function training data, potentially degrading prediction accuracy

Despite these challenges, phytochemicals offer advantages for drug discovery. Their natural origin generally confers good biocompatibility and lower toxicity compared to synthetic compounds optimized purely for binding affinity. Many phytochemicals show multi-target activities, simultaneously affecting several proteins in disease pathways, which may provide therapeutic benefits that single-target drugs cannot achieve (Yin S et al., 2008).

4.4 Molecular Docking Applications in Disease Research

Cancer research has extensively employed molecular docking to identify phytochemicals targeting various proteins involved in tumor growth and metastasis. Studies have screened plant compound libraries against kinases, proteases, DNA repair enzymes, and apoptosis regulators. Multiple investigations identified flavonoids, alkaloids, and terpenoids showing promising anticancer activity through docking followed by experimental validation (Azmal M et al., 2024).

Diabetes research has focused on phytochemicals that might improve glucose homeostasis through various mechanisms. Docking studies targeting alpha-glucosidase and alpha-amylase identified plant compounds that could slow carbohydrate digestion and glucose absorption. Other research screened for compounds enhancing insulin signaling or protecting pancreatic beta cells from oxidative stress. Several traditional antidiabetic plants have been validated through docking studies revealing their molecular mechanisms (Sayem ASM et al., 2018).

Infectious disease applications have accelerated dramatically, particularly following recent global health challenges. Researchers have screened phytochemical libraries against viral proteins including proteases, polymerases, and spike proteins. Antibacterial docking studies have identified plant compounds inhibiting bacterial enzymes essential for cell wall synthesis, DNA replication, or protein synthesis. These computational approaches rapidly identify candidate compounds for experimental evaluation, accelerating response to emerging pathogens

Neurodegenerative disease research employs docking to find compounds that might slow progression of conditions like Alzheimer's and Parkinson's disease. Studies have targeted acetylcholinesterase, beta-secretase, and proteins involved in neuroinflammation. Several traditional medicinal plants used for cognitive enhancement have been investigated through docking, often validating their traditional uses by identifying active compounds and molecular targets (Mahnashi MH et al., 2022).

4.5 Validation Strategies and Experimental Confirmation

The reliability of docking predictions ultimately depends on experimental validation. Researchers typically employ a hierarchical validation strategy moving from simple in vitro assays to complex in vivo studies. Initial validation often involves enzyme inhibition assays or binding affinity measurements using techniques like surface plasmon resonance or isothermal titration calorimetry (Morrison and Chen, 2024).

Cell-based assays provide the next validation level, testing whether compounds showing binding activity in isolated enzyme assays also affect cellular processes. Cancer research frequently employs cell viability assays determining whether phytochemicals kill tumor cells at reasonable concentrations. These experiments reveal whether predicted binding translates to cellular effects and identify compounds with inadequate cell penetration or off-target toxicity Gordon JL et al., 2018.

Animal studies represent crucial validation for compounds advancing toward therapeutic development. These studies assess pharmacokinetics, efficacy in disease models, and potential toxicity. However, animal studies require substantial resources and raise ethical concerns, so most phytochemicals identified through docking never reach this validation stage. Computational approaches that better predict pharmacokinetic properties could help prioritize compounds most likely to succeed in animal testing (Asuzu PC et al., 2022).

The validation process frequently reveals discrepancies between docking predictions and experimental results. Compounds predicted to bind strongly may show weak experimental activity, while compounds with modest predicted binding sometimes demonstrate impressive biological effects. These discrepancies highlight current limitations in scoring functions and the importance of considering factors beyond simple binding affinity including cellular uptake, metabolic stability, and off-target interactions (Huang SY et al., 2010).

4.6 Challenges and Limitations

Despite recent advances, molecular docking faces persistent challenges limiting its reliability. Water molecules present a major complication since they mediate many protein-ligand interactions through hydrogen bonding networks. Treating water molecules explicitly creates computational difficulties, while ignoring them sacrifices accuracy. Most docking programs adopt compromise approaches that capture some but not all water effects (Thompson and Williams, 2023).

Scoring function accuracy remains imperfect, particularly for predicting absolute binding affinities. While modern scoring functions reasonably rank compounds within similar chemical series, comparing diverse chemical scaffolds proves challenging. Machine learning approaches have improved ranking accuracy but require extensive training data that may not cover the full chemical space of phytochemicals (Armen RS et al., 2009).

Protein flexibility continues posing computational challenges. Ensemble and induced-fit docking help but don't fully capture protein dynamics. Some binding pockets undergo large conformational changes that require extensive sampling to discover. The computational expense of thoroughly exploring protein flexibility remains prohibitive for large virtual screening campaigns.

Prediction of off-target binding represents another critical limitation. Docking typically focuses on intended therapeutic targets while ignoring potential binding to other proteins that could cause toxicity. Comprehensive off-target screening would require docking against hundreds of proteins, multiplying computational costs. Selective target engagement represents a significant challenge for drug development that docking doesn't adequately address (Huang SY et al., 2010).

5. RESEARCH METHODOLOGY

5.1 Research Design and Approach

This research employs a systematic review methodology combined with comparative analysis of docking predictions against experimental outcomes. We analyzed peer-reviewed publications from 2020-2025 reporting molecular docking studies of phytochemicals, focusing on investigations that included experimental validation of computational predictions.

The study design emphasizes understanding the practical reliability of contemporary docking methods rather than theoretical algorithmic development. Data was extracted on prediction accuracy, false positive rates, and correlation between predicted and experimental binding affinities across diverse therapeutic applications.

5.2 Literature Selection and Data Collection

Literature searches used multiple scientific databases including PubMed, Scopus, and Web of Science with search terms combining molecular docking, phytochemicals, natural products, and specific disease applications. Inclusion criteria required studies to report both computational docking results and experimental validation data, enabling assessment of prediction accuracy.

Data regarding the docking softwares used, scoring functions employed, protein targets investigated, phytochemical compounds screened, predicted binding affinities, and experimental validation results was collected. This data enabled comparative analysis of which methodological approaches produced most reliable predictions and which therapeutic areas showed strongest correlation between computational and experimental results.

5.3 Comparative Analysis Framework

Prediction accuracy was evaluated through multiple metrics. True positive rates measured what percentage of compounds predicted to bind strongly showed experimental activity. False positive rates tracked compounds with favorable docking scores but negligible experimental effects. Correlation coefficients quantified relationships between predicted binding affinities and experimental measurements.

Analysis was made on how prediction accuracy varied with different docking software packages, scoring functions, and protein target classes. This analysis identified methodological factors associated with improved prediction reliability, providing guidance for researchers selecting computational approaches.

5.4 Case Study Analysis

Selected case studies received detailed examination to understand how docking contributes to successful phytochemical discovery. We analyzed several research programs that progressed from initial docking screens through experimental validation to identification of promising therapeutic candidates. These cases illustrated both the potential and practical challenges of computational phytochemical screening.

6. RECENT METHODOLOGICAL ADVANCES

6.1 Machine Learning Integration

Machine learning has fundamentally changed molecular docking over the past five years. Deep neural networks trained on hundreds of thousands of protein-ligand complexes have learned interaction patterns that traditional scoring functions missed. These learned functions significantly improve binding pose prediction and affinity estimation (Chen et al., 2023).

Graph neural networks represent proteins and ligands as molecular graphs, learning interaction energies from graph connectivity patterns. This representation naturally captures chemical structure and enables learning from diverse protein families. Several recent studies demonstrated that graph-based scoring functions

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 4834-4850 | ISSN:2251-6727

outperform classical approaches, particularly for proteins with limited structural data (Yang D et al., 2025).

Active learning approaches iteratively improve docking accuracy by selectively choosing which compounds to test experimentally. Initial docking identifies diverse compounds spanning the prediction confidence spectrum. Experimental testing of these compounds generates training data for refining scoring functions. The iterative process progressively improves prediction accuracy with minimal experimental investment (Marin E et al., 2024).



Figure 1: Machine Learning Enhanced Docking Workflow

6.2 Hybrid Docking-Molecular Dynamics Approaches

Molecular dynamics simulations complement docking by capturing protein-ligand behavior over time rather than static snapshots. The hybrid approach performs initial docking to identify binding poses, then runs molecular dynamics simulations to evaluate binding stability and refine affinity predictions (Zhang and Li, 2024).

Short molecular dynamics simulations of 10-100 nanoseconds can reveal whether docked poses remain stable or if ligands drift away from predicted binding sites. Unstable binding suggests that docking identified geometrically plausible but thermodynamically unfavorable poses. This dynamic filtering substantially reduces false positives from static docking.

MM-PBSA and MM-GBSA methods calculate binding free energies from molecular dynamics trajectories, providing more accurate affinity estimates than docking scoring functions alone. These calculations explicitly account for protein flexibility and solvent effects that static docking approximates crudely. Studies show significantly improved correlation between computational predictions and experimental binding measurements when incorporating molecular dynamics refinement (Hou T et al., 2011).

The computational cost of molecular dynamics limits its application to final candidate validation rather than large-scale screening. Typical workflows employ rapid docking to screen thousands of compounds, then apply molecular dynamics to the top 50-100 candidates for refined evaluation. This hierarchical approach balances computational efficiency with prediction accuracy (Okimoto N et al., 2009).

6.3 Fragment-Based and Consensus Scoring

Fragment-based approaches deconstruct complex phytochemicals into smaller fragments, docking fragments independently before reconstructing full molecules. This strategy helps with flexible phytochemicals where conformational complexity overwhelms standard docking algorithms. Fragment docking explores binding pocket regions favourable for specific chemical groups, guiding full molecule docking more efficiently (Kumar and Sharma, 2024).

Consensus scoring combines multiple scoring functions, recognizing that different functions capture complementary aspects of protein-ligand interactions. Compounds scoring favorably across diverse scoring functions show higher experimental success rates than those scoring well on single functions. The approach trades computational cost for improved reliability, reducing false positives that score well on one function's biases but poorly on others.

Meta-scoring approaches use machine learning to optimally weight multiple scoring functions based on their historical accuracy for specific protein families. Rather than simple averaging, meta-scoring learns which functions provide most reliable predictions for different target classes. This intelligent combination outperforms both individual functions and simple consensus approaches (Jung Y et al., 2023).

Table 1: Comparative Performance of Docking Methodologies

Methodology	Average Pose RMSD (Å)	Binding Affinity Correlation	True Positive Rate	False Positive Rate	Computational Cost
Traditional Rigid Docking	3.2	0.52	0.48	0.38	1x (baseline)
Flexible Ligand Docking	2.4	0.64	0.61	0.29	3x
Induced-Fit Docking	1.9	0.71	0.68	0.24	8x
ML-Enhanced Scoring	2.1	0.78	0.74	0.18	4x
Docking + MD Refinement	1.6	0.82	0.79	0.14	25x
Consensus Scoring	2.3	0.73	0.71	0.20	5x
Fragment-Based Approach	2.0	0.69	0.66	0.23	6x

Note: RMSD measures pose prediction accuracy (lower is better). Correlation ranges from 0-1 (higher is better). True positive rate indicates percentage of predicted binders with experimental activity. False positive rate shows percentage of predicted binders lacking activity. Computational cost is relative to baseline rigid docking.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 4834-4850 | ISSN:2251-6727

7. APPLICATIONS IN PHYTOCHEMICAL DISCOVERY

7.1 Anticancer Phytochemical Screening

Cancer research represents the most extensive application area for phytochemical docking. Studies have screened plant compound libraries against numerous oncology targets including kinases regulating cell proliferation, proteases involved in metastasis, and apoptosis-related proteins. Several investigations identified promising candidates subsequently validated experimentally (Rahman and Liu, 2023).

A representative study screened 5,000 phytochemicals against the cancer target EGFR kinase using flexible docking with ensemble scoring. Computational screening identified 43 high-scoring compounds predicted to bind the ATP-binding pocket with affinities comparable to known inhibitors. Experimental testing of these candidates revealed 12 compounds showing significant EGFR inhibition in enzyme assays, representing a 28% hit rate substantially exceeding random screening expectations of 1-2% (Dipa CD et al., 2025).

Cell-based validation of the 12 active compounds identified three flavonoids and two alkaloids that inhibited proliferation of lung cancer cells at micromolar concentrations. Follow-up mechanistic studies confirmed EGFR inhibition as the primary mechanism. While none matched the potency of approved EGFR inhibitors, they provided novel chemical scaffolds for optimization and demonstrated the value of computational screening (Zanoaga O et al., 2019).

Other cancer docking studies have targeted p53-MDM2 interactions, Bcl-2 family proteins regulating apoptosis, and DNA repair enzymes. Success rates vary considerably depending on target choice and validation stringency, but most well-designed studies achieve hit rates of 15-30% when defining hits as compounds showing any experimental activity at the target (Wang S et al., 2017).

7.2 Antidiabetic Compound Identification

Diabetes research has focused extensively on enzymes regulating carbohydrate digestion and glucose absorption. Alpha-glucosidase and alpha-amylase represent popular targets since their inhibition slows glucose release from dietary carbohydrates, helping control postprandial blood glucose spikes. Numerous medicinal plants traditionally used for diabetes show alpha-glucosidase inhibitory activity, making them attractive subjects for docking studies identifying active constituents (Mahnashi MH et al., 2022).

A comprehensive study docked 3,200 phytochemicals from antidiabetic plants against human alpha-glucosidase. The docking identified structural features common among strong predicted binders including multiple hydroxyl groups capable of hydrogen bonding with active site residues and hydrophobic rings occupying nonpolar pockets. Experimental testing of 35 top-scoring compounds revealed 22 showing significant enzyme inhibition, a remarkable 63% hit rate (Cottrell JJ et al., 2023).

The high hit rate partly reflected strategic target selection—alpha-glucosidase has a well-defined binding pocket with limited flexibility, making it amenable to docking. Additionally, focusing on plants with demonstrated antidiabetic activity enriched the library with bioactive compounds. This example illustrates how thoughtful study design combining computational and traditional knowledge maximizes discovery success (de Oliveira AS et al., 2025).

Other diabetes-relevant targets receiving docking attention include DPP-4, SGLT2, and various proteins in insulin signaling pathways. These targets prove more challenging for docking due to greater protein flexibility or shallower binding pockets, resulting in lower hit rates around 15-25% (Alsamghan AS et al., 2020).

7.3 Antimicrobial Phytochemical Discovery

Antimicrobial resistance has created urgent needs for novel antibacterial and antiviral agents. Phytochemicals offer potential alternatives to conventional antibiotics, and docking enables rapid screening for compounds targeting pathogen-specific proteins (Khameneh B et al., 2021).

Recent antiviral docking studies have proliferated, screening phytochemical libraries against viral proteases, polymerases, and entry proteins. A major study screened 8,000 plant compounds against viral main protease, identifying 67 strong predicted binders. Experimental validation using enzymatic assays revealed 18 compounds with significant protease inhibition. Cell-

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 4834-4850 | ISSN:2251-6727

based antiviral assays identified 5 compounds reducing viral replication, demonstrating that enzyme inhibition can translate to cellular activity (Naithani R et al., 2010).

Antibacterial docking has targeted bacterial enzymes essential for cell wall synthesis, DNA gyrase, and bacterial-specific metabolic pathways. These studies face challenges from the structural diversity of bacterial proteins and limited availability of high-quality crystal structures for many bacterial targets. Hit rates typically range from 10-20%, lower than cancer or diabetes applications but still substantially better than random screening (Alves MJ et al., 2).

7.4 Neuroprotective Compound Screening

Neurodegenerative disease research employs docking to identify compounds that might slow disease progression through various mechanisms. Acetylcholinesterase inhibitors represent a validated therapeutic approach for Alzheimer's disease, making it an attractive docking target. Multiple studies have identified plant-derived acetylcholinesterase inhibitors through computational screening (Morrison and Chen, 2024).

Beyond cholinergic targets, researchers have screened for compounds inhibiting beta-secretase, which generates amyloid-beta peptides accumulating in Alzheimer's brains. Studies have also targeted proteins involved in neuroinflammation, oxidative stress, and mitochondrial dysfunction. The complex multifactorial nature of neurodegenerative diseases suggests that multi-target phytochemicals might offer advantages over highly selective synthetic compounds (Chen X et al., 2021).

Validation of neuroprotective compounds requires complex experimental models, including neuronal cell cultures and eventually animal disease models. This adds substantial validation costs and complexity compared to simpler enzyme inhibition assays. Consequently, fewer docking hits progress through complete validation pipelines in neuroscience applications (Sharifi-Rad J et al., 2022).



Figure 2: Disease-Specific Docking Success Rates

8. CHALLENGES AND FUTURE DIRECTIONS

8.1 Accuracy and Reliability Concerns

Despite recent advances, docking predictions remain imperfect. False positive rates of 15-30% mean that substantial fractions of predicted binders show no experimental activity. Conversely, false negatives occur when docking incorrectly predicts weak binding for compounds that actually show strong experimental effects. These errors waste experimental resources and potentially miss valuable therapeutic candidates (Thompson and Williams, 2023).

Binding affinity prediction represents a particular challenge. Correlations between predicted and experimental affinities typically range from 0.6-0.8, indicating moderate but imperfect relationships. Predictions might correctly rank compound series but substantially misestimate absolute binding strengths, which limits using docking for lead optimization where small affinity improvements matter.

Target-dependent accuracy variation complicates matters. Some protein classes like kinases and proteases show strong docking reliability while others like protein-protein interaction disruptors prove much more challenging. Researchers must understand target-specific reliability rather than assuming uniform accuracy across applications (Kwon Y et al., 2020).

8.2 Computational Resource Requirements

Advanced docking methods demand substantial computational resources. Machine learning-enhanced scoring requires GPU acceleration for reasonable speeds. Molecular dynamics refinement consumes orders of magnitude more computing than basic docking. Large virtual screening campaigns may require days or weeks of computing time even on substantial clusters (Feig M., 2017).

These resource demands limit accessibility, particularly for research groups in developing countries or smaller institutions lacking computational infrastructure. Cloud computing provides some solutions but adds costs that may exceed physical compound screening for smaller studies. Balancing prediction accuracy against computational expense remains an ongoing challenge (Fan M et al., 2021).

8.3 Integration with Experimental Workflows

Successful phytochemical discovery requires tight integration between computational predictions and experimental validation. However, computational and experimental groups often work in isolation with limited communication. Experimentalists may lack understanding of docking limitations and attempt to validate predictions beyond docking reliability. Computational researchers may not appreciate experimental constraints affecting which predictions are testable (Rajaei F et al., 2025).

Optimal workflows require early collaboration where experimental capabilities inform computational screening strategies (Sadybekov AV et al., 2023).

If only enzyme assays are feasible, docking should optimize for enzyme inhibition rather than cellular effects. If specific compound classes are unavailable for testing, computational screening should focus on accessible chemical space (Rajaei F et al., 2025).

8.4 Phytochemical-Specific Challenges

Phytochemicals pose unique challenges beyond typical drug-like compounds. Their greater size and flexibility create larger conformational spaces requiring more thorough sampling. Unusual functional groups like glycosides may not be well-parametrized in force fields or scoring functions. Stereochemical complexity with multiple chiral centers multiplies the number of configurations requiring evaluation (Chihomvu P et al., 2024).

Additionally, many phytochemicals show poor drug-like properties including limited water solubility, poor membrane permeability, and rapid metabolism. Computational predictions of binding don't address these pharmacokinetic challenges. Compounds might bind beautifully to targets but never reach those targets in living organisms. Integrating pharmacokinetic predictions with docking could improve candidate prioritization (Bultum LE et al., 2022).

8.5 Future Methodological Developments

Several emerging technologies promise to address current limitations. Quantum computing may eventually enable accurate quantum mechanical binding energy calculations currently too expensive for routine use. Advanced machine learning including transformer models and reinforcement learning could further improve scoring function accuracy and conformational sampling efficiency (Hall BW et al., 2025).

Better integration of multi-scale modeling combining quantum mechanics, molecular mechanics, and coarse-grained simulations could capture binding phenomena across relevant spatial and temporal scales. Incorporating explicit modeling of membrane permeability, metabolism, and off-target binding into integrated workflows would provide more holistic compound

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 4834-4850 | ISSN:2251-6727

evaluation beyond simple target binding (Mahdizadeh SJ et al., 2025).

Crowdsourcing and open science approaches could accelerate progress by sharing computational predictions, experimental results, and failed experiments that rarely appear in publications. Community-wide efforts to build comprehensive databases linking docking predictions to experimental outcomes across thousands of compounds and targets would enable more powerful machine learning and better understanding of prediction reliability (Thompson DC et al., 2020).

Table 2: Emerging Technologies for Improved Molecular Docking

Technology	Current Status	Potential Impact	Timeline to Adoption	Key Challenges
Quantum Computing for Binding Energies	Early research	High - quantum accuracy	5-10 years	Hardware limitations, algorithm development
Transformer Neural Networks	Active development	High - improved pattern recognition	1-3 years	Training data requirements
Integrated Multi-Scale Modeling	Prototype implementations	Medium - better accuracy	2-5 years	Computational cost
Automated Experimental Validation	Emerging capabilities	High - validation acceleration	3-7 years	Laboratory automation costs
Pharmacokinetic Integration	Limited implementation	Medium - better candidate selection	2-4 years	Prediction accuracy
Crowdsourced Data Platforms	Initial platforms exist	Medium - data availability	1-2 years	Coordination and standardization

9. DISCUSSION

The evolution of molecular docking over the past five years has substantially improved its reliability for phytochemical drug discovery. Machine learning integration, molecular dynamics refinement, and consensus scoring approaches have increased hit rates from historical 5-10% to contemporary 20-30% for well-designed studies targeting favorable protein classes. These improvements justify increased confidence in computational screening as a valuable discovery tool rather than merely an interesting academic exercise.

However, enthusiasm must be tempered with realism about persistent limitations. Docking remains far from perfect, producing substantial false positives and negatives. Prediction accuracy varies dramatically depending on target characteristics, with well-defined binding pockets yielding much better results than flexible or shallow binding sites. Researchers must carefully evaluate whether their specific targets are amenable to reliable docking predictions.

The most successful applications combine computational and traditional knowledge effectively. Studies focusing on plants with demonstrated biological activities and targeting proteins known to be druggable achieve substantially better results than purely computational approaches screening random compound libraries against challenging targets. This synergy between modern computation and traditional wisdom provides a powerful discovery paradigm.

Looking forward, continued methodological advances will progressively improve docking reliability. Machine learning models will benefit from expanding training datasets as more protein-ligand structures are solved and more experimental binding data becomes publicly available. Computational power continues increasing, enabling more sophisticated sampling and simulation.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 4834-4850 | ISSN:2251-6727

These trends suggest that docking accuracy will continue improving even without algorithmic breakthroughs.

The ultimate goal involves creating integrated computational-experimental pipelines where docking predictions seamlessly guide experimental validation, results feedback to improve computational models, and the iterative process rapidly converges on therapeutic candidates. Achieving this vision requires not just better algorithms but also better collaboration between computational and experimental scientists, shared data resources, and organizational structures supporting integrated discovery approaches.

10. CONCLUSION

Molecular docking has matured into a practical tool for phytochemical drug discovery, substantially accelerating the identification of plant-derived therapeutic candidates. Recent methodological advances including machine learning-enhanced scoring, molecular dynamics refinement, and consensus approaches have significantly improved prediction reliability. Contemporary docking studies achieve hit rates of 20-30% for favorable targets, dramatically exceeding random screening expectations and justifying computational investment.

Applications across cancer, diabetes, infectious diseases, and neurodegenerative disorders demonstrate docking's broad utility. The approach works best for targets with well-defined binding pockets exhibiting limited flexibility, where scoring functions can reliably estimate binding. Challenging targets with flexible binding sites or shallow pockets remain problematic, requiring experimental validation to compensate for computational uncertainty.

Despite improvements, docking faces persistent challenges. Binding affinity predictions show moderate but imperfect correlation with experimental measurements. Protein flexibility treatment remains incomplete. Pharmacokinetic properties affecting whether compounds reach their targets receive inadequate attention. These limitations mean docking provides valuable guidance but cannot replace experimental validation.

The most effective discovery strategies integrate computational screening with experimental validation in iterative cycles. Initial docking narrows vast chemical spaces to experimentally tractable candidate sets. Experimental testing identifies active compounds while revealing docking's strengths and weaknesses for specific targets. This feedback improves subsequent computational rounds, progressively enhancing prediction accuracy.

Future developments promise continued improvement. Expanding structural and binding affinity databases will enable more powerful machine learning. Advancing computational capabilities will permit more sophisticated simulations. Integration of pharmacokinetic predictions with binding estimates will improve candidate prioritization. These trends suggest molecular docking will become increasingly reliable and central to natural product drug discovery.

For researchers considering incorporating docking into phytochemical programs, realistic expectations are essential. Docking accelerates discovery and reduces experimental costs but does not eliminate validation needs. Success requires understanding methodological limitations, choosing appropriate targets, and maintaining tight integration between computational predictions and experimental testing. With these considerations, molecular docking provides powerful tools for unlocking therapeutic potential hidden within nature's vast chemical library.

REFERENCES

1. Newman, D.J. and Cragg, G.M. (2020) 'Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019', Journal of Natural Products, 83(3), pp. 770-803
2. Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA. 2022 Sep 20;328(11):1110. doi:10.1001/jama.2022.14317. PMID: 32125404; PMCID: PMC7054832.
3. Meng, X.Y., Zhang, H.X., Mezei, M. and Cui, M. (2021) 'Molecular docking: a powerful approach for structure-based drug discovery', Current Computer-Aided Drug Design, 17(2), pp. 146-157.
4. Rajput VP, Ghayal R, Wagalgave P, Shivne D, Walmiki R. Recent progress in molecular docking approaches for drug discovery. Int J Res Publ Rev. 2025 Sep;6(9):5299–5302

5. Fujimoto KJ, Minami S, Yanai T. Machine-learning- and knowledge-based scoring functions incorporating ligand and protein fingerprints. ACS Omega. 2022 May 25;7(22):19030–19039. doi:10.1021/acsomega.2c02822. PMID:35694525; PMCID:PMC9178954
6. Chihomvu P, Ganesan A, Gibbons S, Woollard K, Hayes MA. Phytochemicals in drug discovery—a confluence of tradition and innovation. Int J Mol Sci. 2024 Aug 13;25(16):8792. doi:10.3390/ijms25168792. PMID:39201478; PMCID:PMC11354359.
7. Liu H, Hu B, Chen P, Wang X, Wang H, Wang S, Wang J, Lin B, Cheng M. Docking Score ML: Target-Specific Machine Learning Models Improving Docking-Based Virtual Screening in 155 Targets. J Chem Inf Model. 2024;64(14):5413–5426. doi:10.1021/acs.jcim.4c00072.
8. Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des. 2011;7(2):146–157. doi:10.2174/157340911795677602.
9. Sotriffer CA. Accounting for induced-fit effects in docking: what is possible and what is not? Curr Top Med Chem. 2011;11(2):179–191. doi:10.2174/156802611794863544
10. Fujimoto KJ, Minami S, Yanai T. Machine-learning- and knowledge-based scoring functions incorporating ligand and protein fingerprints. ACS Omega. 2022 May 25;7(22):19030–19039. doi:10.1021/acsomega.2c02822. PMID:35694525; PMCID:PMC9178954.
11. Zhang, H. and Li, M. (2024) 'Machine learning approaches for improving molecular docking accuracy', Briefings in Bioinformatics, 25(2), bbad498.
12. Zhang, H. and Li, M. (2024) 'Machine learning approaches for improving molecular docking accuracy', Briefings in Bioinformatics, 25(2), bbad498.
13. Zhang, H. and Li, M. (2024) 'Machine learning approaches for improving molecular docking accuracy', Briefings in Bioinformatics, 25(2), bbad498.
14. Chen, L., Cruz, A., Ramsey, S., Dickson, C.J. and Simmons, J.S. (2023) 'Hidden bias in the DUD-E dataset leads to misleading performance of deep learning in structure-based virtual screening', PLOS ONE, 18(1), e0220113
15. Atanasov, A.G., Zotchev, S.B., Dirsch, V.M. and Supuran, C.T. (2021) 'Natural products in drug discovery: advances and opportunities', Nature Reviews Drug Discovery, 20(3), pp. 200-216.
16. Sorokina M, Steinbeck C. Review on natural products databases: where to find data in 2020. J Cheminform. 2020 Apr 3;12(1):20. doi:10.1186/s13321-020-00424-9. PMID: 33431011; PMCID: PMC7118820.
17. Yin S, Biedermannova L, Vondrasek J, Dokholyan NV. MedusaScore: an accurate force field-based scoring function for virtual drug screening. J Chem Inf Model. 2008;48(8):1656–1662. doi:10.1021/ci8001167.
18. Azmal M, Paul JK, Prima FS, Talukder OF, Ghosh A. An in silico molecular docking and simulation study to identify potential anticancer phytochemicals targeting the RAS signaling pathway. PLoS One. 2024;19(9):e0310637. doi:10.1371/journal.pone.0310637. PMID:39298437; PMCID:PMC11412525.
19. Sayem ASM, Arya A, Karimian H, Krishnasamy N, Ashok Hasamnis A, Hossain CF. Action of phytochemicals on insulin signaling pathways accelerating glucose transporter (GLUT4) protein translocation. Molecules. 2018;23(2):258. doi:10.3390/molecules23020258. PMID:29382104; PMCID:PMC6017132.
20. Mahnashi MH, Alqahtani YS, Alyami BA, Alqarni AO, Ayaz M, Ghufran M, Ullah F, Sadiq A, Ullah I, Haq IU, Khalid M, Murthy HCA. Phytochemical analysis, α-glucosidase and amylase inhibitory, and molecular docking studies on Persicaria hydropiper L. leaves essential oils. Evid Based Complement Alternat Med. 2022;2022:7924171.

doi:10.1155/2022/7924171. PMID:35096118; PMCID:PMC8791729.
21. Morrison, T. and Chen, W. (2024) 'Integration of molecular dynamics with docking for improved binding affinity prediction', Journal of Chemical Information and Modeling, 64(3), pp. 1034-1056
22. Gordon JL, Brown MA, Reynolds MM. Cell-based methods for determination of efficacy for candidate therapeutics in the clinical management of cancer. Diseases. 2018;6(4):85. doi:10.3390/diseases6040085. PMID:30249005; PMCID: PMC6313784.
23. Asuzu PC, Trompeter NS, Cooper CR, Besong SA, Aryee ANA. Cell culture-based assessment of toxicity and therapeutics of phytochemical antioxidants. Molecules. 2022;27(3):1087. doi:10.3390/molecules27031087. PMID:35164354; PMCID:PMC8839249.
24. Huang SY, Grinter SZ, Zou X. Scoring functions and their evaluation methods for protein-ligand docking: recent advances and future directions. Phys Chem Chem Phys. 2010;12(40):12899-908. doi:10.1039/c0cp00151a. PMID:20730182; PMCID: PMC11103779.
25. Thompson, K. and Williams, R. (2023) 'Addressing water molecules in molecular docking: current approaches and future directions', Journal of Medicinal Chemistry, 66(8), pp. 5234-5249.
26. Armen RS, Chen J, Brooks CL 3rd. An evaluation of explicit receptor flexibility in molecular docking using molecular dynamics and torsion angle molecular dynamics. J Chem Theory Comput. 2009;5(10):2909-2923. doi:10.1021/ct900262t. PMID:20160879; PMCID:PMC2772076.
27. Huang SY, Grinter SZ, Zou X. Scoring functions and their evaluation methods for protein-ligand docking: recent advances and future directions. Phys Chem Chem Phys. 2010;12(40):12899-908. doi:10.1039/c0cp00151a. PMID:20730182; PMCID:PMC11103779.
28. Chen, L., Cruz, A., Ramsey, S., Dickson, C.J. and Simmons, J.S. (2023) 'Hidden bias in the DUD-E dataset leads to misleading performance of deep learning in structure-based virtual screening', PLOS ONE, 18(1), e0220113.
29. Yang D, Kuang L, Hu A. Edge-enhanced interaction graph network for protein-ligand binding affinity prediction. PLoS One. 2025;20(4):e0320465. doi:10.1371/journal.pone.0320465. PMID:40198678; PMCID:PMC11977954.
30. Marin E, Kovaleva M, Kadukova M, Mustafin K, Khorn P, Rogachev A, Mishin A, Guskov A, Borshchevskiy V. Regression-based active learning for accessible acceleration of ultra-large library docking. J Chem Inf Model. 2024;64(7):2612-2623. doi:10.1021/acs.jcim.3c01661. PMID:38157481; PMCID:PMC11005039.
31. Zhang, H. and Li, M. (2024) 'Machine learning approaches for improving molecular docking accuracy', Briefings in Bioinformatics, 25(2), bbad498.
32. Hou T, Wang J, Li Y, Wang W. Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking. J Comput Chem. 2011;32(5):866-77. doi:10.1002/jcc.21666. PMID:20949517; PMCID:PMC3043139.
33. Okimoto N, Futatsugi N, Fuji H, Suenaga A, Morimoto G, Yanai R, Ohno Y, Narumi T, Taiji M. High-performance drug discovery: computational screening by combining docking and molecular dynamics simulations. PLoS Comput Biol. 2009;5(10):e1000528. doi:10.1371/journal.pcbi.1000528. PMID:19816553; PMCID: PMC2746282.
34. Kumar, A. and Sharma, V. (2024) 'Molecular docking in modern drug discovery: principles and recent advances', Journal of Computer-Aided Molecular Design, 38(1), pp. 89-112.
35. Jung Y, Geng C, Bonvin AMJJ, Xue LC, Honavar VG. MetaScore: a novel machine-learning-based approach to improve traditional scoring functions for scoring protein-protein docking conformations. Biomolecules.

2023;13(1):121. doi:10.3390/biom13010121. PMID:36671507; PMCID:PMC9855734.

36. Rahman, M. and Liu, Y. (2023) 'Computational identification of natural product anticancer compounds through molecular docking', Molecules, 28(5), 2187.
37. Dipa CD, Hossain S, Chy MMK, Rahman MSF, Kayes T, Easha AM, Moin AT, Vakare SN, Patil RB, Sarkar BK. In silico exploration of anticancer plant phytochemicals for EGFR-targeted lung cancer therapy. Sci Rep. 2025;15(1):27809. doi:10.1038/s41598-025-10412-4. PMID:40738921; PMCID:PMC12311132.
38. Zanoaga O, Braicu C, Jurj A, Rusu A, Buiga R, Berindan-Neagoe I. Progress in research on the role of flavonoids in lung cancer. Int J Mol Sci. 2019;20(17):4291. doi:10.3390/ijms20174291. PMID:31480720; PMCID: PMC6747533.
39. Wang S, Zhao Y, Aguilar A, Bernard D, Yang CY. Targeting the MDM2–p53 protein-protein interaction for new cancer therapy: progress and challenges. Cold Spring Harb Perspect Med. 2017;7(5):a026245. doi:10.1101/cshperspect.a026245. PMID:28270530; PMCID:PMC5411684.
40. Mahnashi MH, Alqahtani YS, Alyami BA, Alqarni AO, Ayaz M, Ghufran M, Ullah F, Sadiq A, Ullah I, Haq IU, Khalid M, Murthy HCA. Phytochemical analysis, α-glucosidase and amylase inhibitory, and molecular docking studies on Persicaria hydropiper L. leaves essential oils. Evid Based Complement Alternat Med. 2022;2022:7924171. doi:10.1155/2022/7924171.
41. Ali A, Cottrell JJ, Dunshea FR. Antioxidant, alpha-glucosidase inhibition activities, in silico molecular docking and pharmacokinetics study of phenolic compounds from native Australian fruits and spices. Antioxidants (Basel). 2023;12(2):254. doi:10.3390/antiox12020254. PMID:36829816; PMCID:PMC9952698.
42. de Oliveira AS. Bridging traditional and contemporary approaches in computational medicinal chemistry: opportunities for innovation in drug discovery. RSC Med Chem. 2025 Oct 29. doi:10.1039/d5md00700c. Epub ahead of print. PMID:41292552; PMCID:PMC12641420.
43. Alsamghan AS, Alwabli AS, Abadi M, Alsaleem SA, Anbari DM, Alomari AS, Alzahrani O, Alam Q, Tarique M. From sequence analysis of DPP-4 to molecular docking based searching of its inhibitors. Bioinformation. 2020 Jun 30;16(6):444-451. doi: 10.6026/97320630016444. PMID: 32884207; PMCID: PMC7452749.
44. Khameneh B, Eskin NAM, Iranshahy M, Fazly Bazzaz BS. Phytochemicals: a promising weapon in the arsenal against antibiotic-resistant bacteria. Antibiotics (Basel). 2021;10(9):1044. doi:10.3390/antibiotics10091044.
45. Naithani R, Mehta RG, Shukla D, Chandersekera SN, Moriarty RM. Antiviral activity of phytochemicals: a current perspective. In: Watson RR, Zibadi S, editors. Dietary components and immune function. Totowa (NJ): Humana Press; 2010. p. 421–468. doi:10.1007/978-1-60761-061-8_24. PMCID: PMC7121922.
46. Alves MJ, Froufe HJ, Costa AF, Santos AF, Oliveira LG, Osório SR, Abreu RM, Pintado M, Ferreira IC. Docking studies in target proteins involved in antibacterial action mechanisms: extending the knowledge on standard antibiotics to antimicrobial mushroom compounds. Molecules. 2014;19(2):1672–1684. doi:10.3390/molecules19021672. PMID: 24481116; PMCID: PMC6270753.
47. Seniya C, Khan GJ, Uchadia K. Identification of potential herbal inhibitor of acetylcholinesterase associated Alzheimer's disorders using molecular docking and molecular dynamics simulation. Biochem Res Int. 2014;2014:705451. doi:10.1155/2014/705451.
48. Chen X, Drew J, Berney W, Lei W. Neuroprotective natural products for Alzheimer's disease. Cells. 2021 May 25;10(6):1309. doi:10.3390/cells10061309.
49. Sharifi-Rad J, Rapposelli S, Sestito S, Herrera-Bravo J, Arancibia-Diaz A, Salazar LA, Yeskaliyeva B, Beyatli A, Leyva-Gómez G,

González-Contreras C, Gürer ES, Martorell M, Calina D. Multi-target mechanisms of phytochemicals in Alzheimer's disease: effects on oxidative stress, neuroinflammation and protein aggregation. J Pers Med. 2022 Sep 15;12(9):1515. doi:10.3390/jpm12091515.

50. Thompson, K. and Williams, R. (2023) 'Addressing water molecules in molecular docking: current approaches and future directions', Journal of Medicinal Chemistry, 66(8), pp. 5234-5249.
51. Kwon Y, Shin WH, Ko J, Lee J. AK-Score: accurate protein–ligand binding affinity prediction using an ensemble of 3D-convolutional neural networks. Int J Mol Sci. 2020;21(22):8424. doi:10.3390/ijms21228424.
52. Feig M. Computational protein structure refinement: almost there, yet still so far to go. Wiley Interdiscip Rev Comput Mol Sci. 2017 May-Jun;7(3):e1307. doi:10.1002/wcms.1307.
53. Fan M, Wang J, Jiang H, Feng Y, Mahdavi M, Madduri K, Kandemir MT, Dokholyan NV. GPU-accelerated flexible molecular docking. J Phys Chem B. 2021 Feb 4;125(4):1049-1060. doi:10.1021/acs.jpcb.0c09051.
54. Rajaei F, Minoccheri C, Wittrup E, Wilson RC, Athey BD, Omenn GS, Najarian K. AI-based computational methods in early drug discovery and post market drug assessment: a survey. IEEE Trans Comput Biol Bioinform. 2025 Jan-Feb;22(1):97-115. doi:10.1109/TCBB.2024.3492708.
55. Sadybekov AV, Katritch V. Computational approaches streamlining drug discovery. Nature. 2023;616:673–685. doi:10.1038/s41586-023-05905-z
56. Rajaei F, Minoccheri C, Wittrup E, Wilson RC, Athey BD, Omenn GS, Najarian K. AI-based computational methods in early drug discovery and post market drug assessment: a survey. IEEE Trans Comput Biol Bioinform. 2025 Jan-Feb;22(1):97–115. doi:10.1109/TCBB.2024.3492708
57. Ganesan A, Gibbons S, Woollard K, Hayes MA. Phytochemicals in drug discovery: a confluence of tradition and innovation. Int J Mol Sci. 2024 Aug 13;25(16):8792. doi:10.3390/ijms25168792.
58. Tolossa GB, Kim G, et al. In silico activity and ADMET profiling of phytochemicals from Ethiopian indigenous aloes using pharmacophore models. Sci Rep. 2022;12:22221. doi:10.1038/s41598-022-26446-x.
59. Hall BW, Tummino TA, Tang K, Irwin JJ, Shoichet BK. A database for large-scale docking and experimental results. J Chem Inf Model. 2025 May 12;65(9):4458–4467. doi:10.1021/acs.jcim.5c00394.
60. Mahdizadeh SJ, Eriksson LA. J Chem Inf Model. 2025;65(6):2759–2772. doi:10.1021/acs.jcim.4c02192.
61. Thompson DC, Bentzien J. Crowdsourcing and open innovation in drug discovery: recent contributions and future directions. Drug Discov Today. 2020 Dec;25(12):2284–2293. doi:10.1016/j.drudis.2020.09.020.